HELP (Helus Pharma) Shares Outstanding (EOP): 51.68 Mil (As of Mar. 2026)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.27
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Shares Outstanding (EOP)?

Helus Pharma HELP -4.99% 22 Shares Outstanding (EOP) is 51.68 Mil as of Mar. 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Helus Pharma's shares outstanding for the quarter that ended in Mar. 2026 was 51.68 Mil.

Helus Pharma's quarterly shares outstanding increased from Dec. 2025 (49.89 Mil) to Mar. 2026 (51.68 Mil). It means Helus Pharma issued new shares from Dec. 2025 to Mar. 2026 .

Helus Pharma's annual shares outstanding increased from Mar. 2025 (21.61 Mil) to Mar. 2026 (51.68 Mil). It means Helus Pharma issued new shares from Mar. 2025 to Mar. 2026 .


Helus Pharma  (NAS:HELP) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Helus Pharma Shares Outstanding (EOP) Related Terms


Helus Pharma Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Shares Outstanding (EOP) Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial 4.36 5.15 20.00 21.61 51.68

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.61 23.03 26.10 49.89 51.68

HELP vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Helus Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helus Pharma Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Helus Pharma's Shares Outstanding (EOP) falls into.


HELP
22GF Score
Helus Pharma Inc HELP
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 51.68 Mil mean?
Helus Pharma (HELP) has a Shares Outstanding (EOP) of 51.68 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Helus Pharma and its competitors.
Is Helus Pharma's Shares Outstanding (EOP) too high?
Helus Pharma's current Shares Outstanding (EOP) is 51.68 Mil. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Shares Outstanding (EOP) compare to VRTX and REGN?
Helus Pharma's Shares Outstanding (EOP) of 51.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Helus Pharma and its competitors. Helus Pharma's current Shares Outstanding (EOP) is 51.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Shares Outstanding (EOP) of 51.68 Mil. The current Shares Outstanding (EOP) is 51.68 Mil. Helus Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Helus Pharma (HELP), the current Shares Outstanding (EOP) is 51.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.27
Price